JP2022543669A5 - - Google Patents

Info

Publication number
JP2022543669A5
JP2022543669A5 JP2022507737A JP2022507737A JP2022543669A5 JP 2022543669 A5 JP2022543669 A5 JP 2022543669A5 JP 2022507737 A JP2022507737 A JP 2022507737A JP 2022507737 A JP2022507737 A JP 2022507737A JP 2022543669 A5 JP2022543669 A5 JP 2022543669A5
Authority
JP
Japan
Prior art keywords
antigen
binding molecule
domain
molecule according
target molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022507737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543669A (ja
JP7682853B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/045309 external-priority patent/WO2021026409A1/en
Publication of JP2022543669A publication Critical patent/JP2022543669A/ja
Publication of JP2022543669A5 publication Critical patent/JP2022543669A5/ja
Priority to JP2025080907A priority Critical patent/JP2025114807A/ja
Application granted granted Critical
Publication of JP7682853B2 publication Critical patent/JP7682853B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022507737A 2019-08-08 2020-08-07 新規抗原結合分子フォーマット Active JP7682853B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025080907A JP2025114807A (ja) 2019-08-08 2025-05-14 新規抗原結合分子フォーマット

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962884496P 2019-08-08 2019-08-08
US62/884,496 2019-08-08
US202063050483P 2020-07-10 2020-07-10
US63/050,483 2020-07-10
PCT/US2020/045309 WO2021026409A1 (en) 2019-08-08 2020-08-07 Novel antigen binding molecule formats

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025080907A Division JP2025114807A (ja) 2019-08-08 2025-05-14 新規抗原結合分子フォーマット

Publications (3)

Publication Number Publication Date
JP2022543669A JP2022543669A (ja) 2022-10-13
JP2022543669A5 true JP2022543669A5 (enExample) 2023-08-16
JP7682853B2 JP7682853B2 (ja) 2025-05-26

Family

ID=72179250

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022507737A Active JP7682853B2 (ja) 2019-08-08 2020-08-07 新規抗原結合分子フォーマット
JP2025080907A Pending JP2025114807A (ja) 2019-08-08 2025-05-14 新規抗原結合分子フォーマット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025080907A Pending JP2025114807A (ja) 2019-08-08 2025-05-14 新規抗原結合分子フォーマット

Country Status (12)

Country Link
US (8) US12215148B2 (enExample)
EP (1) EP4010371A1 (enExample)
JP (2) JP7682853B2 (enExample)
KR (1) KR20220058546A (enExample)
CN (3) CN120842426A (enExample)
AU (1) AU2020327000A1 (enExample)
BR (1) BR112022002067A2 (enExample)
CA (1) CA3150168A1 (enExample)
IL (1) IL290371A (enExample)
MX (1) MX2022001682A (enExample)
TW (1) TW202120556A (enExample)
WO (1) WO2021026409A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12060425B2 (en) 2018-05-03 2024-08-13 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
JP7682853B2 (ja) * 2019-08-08 2025-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規抗原結合分子フォーマット
WO2021146464A1 (en) * 2020-01-15 2021-07-22 The Board Of Trustees Of The Leland Stanford Junior University Pericyte-sparing therapy
US20230242605A1 (en) * 2020-06-19 2023-08-03 Sookmyung Women's University Industry-Academic Cooperation Foundation Mutation complex including gain-of-function mutant of bmpr2 gene, induced pluripotent stem cells and mesenchymal stem cells derived from mutant, and use thereof
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
US12350374B2 (en) 2020-12-17 2025-07-08 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2102007T3 (es) 1992-01-23 1997-07-16 Merck Patent Gmbh Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
DK1594542T3 (da) 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
HUE026278T2 (en) 2003-07-01 2016-05-30 Ucb Biopharma Sprl Modified Fab antibody fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
SI1912671T1 (en) 2005-07-18 2018-01-31 Seattle Genetics, Inc. Conjugates beta-glucuronide linker-drug
CN101990441A (zh) 2007-11-28 2011-03-23 默萨那治疗学股份有限公司 生物相容的生物可降解的烟曲霉素类似物轭合物
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
AU2010252284A1 (en) * 2009-05-27 2011-11-17 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
CN102448469A (zh) 2009-05-28 2012-05-09 摩萨纳医疗有限公司 包括具有可变的释放速率的连接物的聚缩醛(酮)-药物共轭物
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
CN102648419B (zh) 2009-12-07 2016-03-16 株式会社Ntt都科摩 传输路径推定方法
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
EP2553019A1 (en) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
CA2798432A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
US20130189218A1 (en) 2011-12-23 2013-07-25 Mersana Therapeutics, Inc. Pharmaceutical formulations for fumagillin derivative-phf conjugates
US20140017265A1 (en) 2012-07-05 2014-01-16 Mersana Therapeutics, Inc. Terminally Modified Polymers and Conjugates Thereof
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
MY185881A (en) 2013-02-20 2021-06-14 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
WO2014144357A1 (en) 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
CN107001482B (zh) * 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
DK3237005T3 (en) 2014-12-22 2024-11-18 Systimmune Inc Bispecific tetravalent antibodies and methods of making and using thereof
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
CA2998174A1 (en) 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
WO2018191438A1 (en) * 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN207626880U (zh) 2017-05-19 2018-07-20 厦门汇成峰户外用品有限公司 一种导演椅
AU2018358883B2 (en) 2017-10-30 2025-09-25 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
PL3704146T3 (pl) * 2017-11-01 2022-03-07 F. Hoffmann-La Roche Ag Przeciwciało Contorsbody trifab
US11754569B2 (en) 2018-08-30 2023-09-12 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
JP7682853B2 (ja) * 2019-08-08 2025-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規抗原結合分子フォーマット

Similar Documents

Publication Publication Date Title
AU2022218544B2 (en) Hetero-dimeric multi-specific antibody format
JP2025114807A5 (enExample)
JP2021042257A5 (enExample)
JP2017504578A5 (enExample)
JP2020508655A5 (enExample)
JP2024532485A5 (enExample)
JP2021159081A5 (enExample)
JP2014158485A5 (enExample)
JP2008511337A5 (enExample)
CA3173414A1 (en) Pd-1 agonist multimeric binding molecules
IL272103B1 (en) Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer
JP2025512953A5 (enExample)
JP2024500335A5 (enExample)
JP2016529213A5 (enExample)
JP2021529524A5 (enExample)
JP2025505611A5 (enExample)
JP2024531915A5 (enExample)
RU2022105671A (ru) Новые форматы антигенсвязывающих молекул
WO2021062033A1 (en) Fusion polypeptides binding antibody fc domains and integrin and methods of use
NZ775540B2 (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
NZ775540A (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
RU2024123283A (ru) Бифункциональная молекула, образованная путем слияния антитела pd1 и интерлейкина 2
JP2024531346A5 (enExample)
JP2024537397A5 (enExample)
JP2024512324A5 (enExample)